A 2025 systematic review in orthopedic sports medicine concluded that BPC-157 promotes healing by boosting growth factors and reducing inflammation, with improved structural and functional recovery across fracture, muscle, tendon, and ligament injury models
Its mechanism of action is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs)
This substitution may enhance the peptides binding affinity to the GHRH receptor
FDA-approved peptides like GLP-1 medications have a risk of side effects like nausea, vomiting, constipation, and diarrhea
Preclinical Safety Evaluation In preclinical studies, BPC 157 did not lead to any serious toxicity in tested animals, including: mice rats rabbits dogs These studies provide a strong foundation for understanding the safety profile of BPC 157, indicating that it is well-tolerated across different species